Risk Partners Life Sciences Roundtable 2024, thank you very much! Sign up now for the 26.06.2025 >

We congratulate Formycon AG on its successful uplisting to the Prime Standard of Deutsche Börse on November 12, 2024!

Welcome to the Prime Standard league: A new champion of life sciences and biosimilars has successfully made the step from the scale segment. We proudly congratulate Enno Spillner, Dr. Caroline Redeker, Daniel Marquard and the entire Formycon AG team on this great success and another important milestone on their way to becoming a global champion in the biosimilars sector!

Formycon AG specializes in the development of high-quality biosimilars, which represent a cost-effective alternative to original biopharmaceutical preparations. The company demonstrates its innovative strength particularly in the field of follow-on molecules and has successfully positioned itself as one of the leading suppliers of biosimilars. With its expertise in research and development, Formycon creates access to cutting-edge biopharmaceutical products that benefit patients worldwide and has now also attracted increasing interest from international investors. As a result, the company has now been listed in the Prime Standard.  

Risk Partners acted as Capital Markets Insurance Advisor in this transaction. Our team, consisting of Florian, Franziska and Björn, supported Formycon AG during the successful uplisting process from the Scale to the Prime Standard of the Frankfurt Stock Exchange on November 12, 2024.

We are particularly pleased to contribute our specialization and expertise as an insurance broker for life sciences and capital market transactions and to accompany a "neighbor" from the Planegg/Martinsried region.

Special thanks also go to our co-broker team at Dr. Ellwanger & Kramm GmbH & Co. KG, in particular Gregor Klingeler and Frieder Lang, for the trust they have placed in us and the great cooperation. If you have a similar project in mind and would appreciate our support, please do not hesitate to contact us about the added value of RP4brokers

Also read our other blog posts

Being Public

Earnings Call: one 0 too many - the Lyft CEO mistake

"Look, it was a bad mistake, and that's on me," CEO of LYFT Inc. The incident and possible insurance coverage. You may have also heard about the recent incident with LYFT. In the quarterly earnings report, LYFT originally stated that profit margins were up 500 basis points before correcting this to 50 basis points during the conference call. This clerical error caused the stock price to rise more than 60% in after-hours trading. This situation is exactly what investor relations teams that

Read more "
Life Sciences

Cyber Risks: Case Study Evotec

Last year, more than 10 percent of German companies were affected by an IT security incident, with the proportion rising due to cyber attacks. Biotechnology is not excluded either. It is possible to learn from the Evotec case. It is about successful cyber attacks or other incidents that are important for security, such as acts of sabotage or hardware theft. According to a representative Ipsos survey conducted on behalf of the TÜV association among 501 companies with more than ten employees. According to the TÜV

Read more "
Life Sciences

Atrialis GmbH - experts in clinical trial insurance

Atrialis GmbH - experts in clinical trial insurance & Risk Partners will play in the same team in the future. LifeSciences - Leading risk concepts for leading science! Under this guiding principle, we have been able to advise innovative companies from the biotechnology, pharmaceutical and medical device sectors comprehensively on risk issues for many years and support them with suitable insurance solutions in all growth and study phases, from foundation to IPO and beyond (e.g. insuring a clinical trial). Together with my team at Risk Partners GmbH, we would like to continue our focus, our passion

Read more "
Management

Research breakdown at Stockholm's Karolinska Institute: A cooling failure destroys cell cultures from decades of research

Research mishap at Stockholm's Karolinska Institute: A cooling failure destroys cell cultures from decades of research - can you insure against it? An incident that threatens your very existence, but which we would like to shed some light on from the perspective of an insurance broker specializing in life sciences. What happened? A cooling system at the Karolinska Institute in Stockholm, Sweden's most important medical research center, failed for five days. Biological material that had been collected over 30 years and, according to the institute, was unique in the world, was destroyed as a result. The material was stored in deep-freeze tanks in which the temperature

Read more "
Management

OLG Schleswig – Statute of Limitations for Liability Claims in the Case of Direct Claims in D&O Insurance

OLG Schleswig: Statute of limitations for liability claims in the case of direct claims in D&O insurance. There is a new, exciting verdict from the world of D&O insurance. Recently, we reported on the decision of the Higher Regional Court of Cologne in the context of the direct lawsuit. Now the Higher Regional Court of Schleswig has also made a groundbreaking decision. What was it about? The focus was on the question of the statute of limitations. However, it must be taken into account that the question of the statute of limitations in the event of a D&O claim is not trivial. On the one hand, there is the original claim for damages (statutory D&O liability

Read more "
Being Public

Revolution in D&O insurance in Nevada (US insurance market) postponed

The revolution in D&O insurance in Nevada has been called off after all. In the US market, the state of Nevada passed an interesting law (Bill No. 398) in the summer with potentially significant implications for the D&O insurance market. The Governor of Nevada approved the bill on June 3, 2023, so the law came into force on October 1, 2023. We had classified this legislation (in the USA, insurance supervision is organized at state level) as too watchful for our clients, but this law

Read more "